FLUZONE HIGH-DOSE DIN 02445646
Status: Marketed
Holder: SANOFI VACCINES CANADA LTD.
Molecule: HAEMAGGLUTININ-STRAIN A (H3N2)
Available to quote
Health Canada record
| Active ingredient(s) | HAEMAGGLUTININ-STRAIN A (H3N2) 60 MCG; HAEMAGGLUTININ-STRAIN B 60 MCG; HAEMAGGLUTININ-STRAIN A (H1N1) 60 MCG |
|---|---|
| Dosage form | Suspension |
| Route | Intramuscular |
| Schedule | SCHEDULE D |
| Class | Human |
| ATC | J07BB02 INFLUENZA, INACTIVATED, SPLIT VIRUS OR SURFACE ANTIGEN |
| Original market date | 27-Sep-2016 |
| Current status date | 10-Sep-2025 |
| Source | Health Canada DPD |
Establishment licence of the holder
Sanofi Vaccines Canada Ltd. — licence 101420, currently licensed, last inspection rating C (2026-02-23).
No Canadian shortage report is currently matched to this DIN.
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 18954 | 2017-02-10 | New Drug Submission (NDS) | TRANSFER OF DRUG IDENTIFICATION NUMBER |
| 17262 | 2015-09-09 | Supplement to a New Drug Submission (SNDS) | FOR ACTIVE IMMUNIZATION AGAINST INFLUENZA CAUSED BY THE SPECIFIC STRAINS OF INFLUENZA VIRUS CONTAINED IN THE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER |